Treatment of cancer by inhibition of the MYD88/ERK MAP kinase interaction
US9683986B2 · kind B2 · utility
0Cited by
0References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 17, 2012 |
| Grant date | Jun 20, 2017 |
| Priority date | — |
| Expiry date | Apr 27, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/10
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.